Prevention of Gastrointestinal Toxicity From Total Body Irradiation or High Dose Chemotherapy With Pasireotide

Trial Profile

Prevention of Gastrointestinal Toxicity From Total Body Irradiation or High Dose Chemotherapy With Pasireotide

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Jul 2017

At a glance

  • Drugs Pasireotide (Primary) ; Busulfan; Methotrexate
  • Indications Graft-versus-host disease
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 17 Feb 2015 Planned End Date changed from 1 Oct 2020 to 1 Jan 2020, according to ClinicalTrials.gov record.
    • 17 Feb 2015 Planned primary completion date changed from 1 Oct 2018 to 1 Jan 2019, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top